Tositumomab: Difference between revisions
Content deleted Content added
stub |
No edit summary |
||
| Line 24: | Line 24: | ||
| routes_of_administration = |
| routes_of_administration = |
||
}} |
}} |
||
'''Tositumomab''' is a [[monoclonal antibody]] derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to Iodine 131. 131I emits both beta and gamma radiation, and is broken down rapidly in the body. |
|||
'''Tositumomab''' is a [[monoclonal antibody]]. |
|||
Clinical trials have established the efficacy of tositumomab in patients with relapsed follicular lymphoma. |
|||
{{treatment-stub}} |
|||
It is manufactured by [[Corixa]]. It sells in the U.S. under the trade name Bexxar.{{treatment-stub}} |
|||
Revision as of 00:52, 23 November 2006
| File:Tositumomab.png | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| DrugBank | |
| Chemical and physical data | |
| Formula | C6416H9874N1688O1987S44 |
| Molar mass | 143859.7 g/mol |
Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to Iodine 131. 131I emits both beta and gamma radiation, and is broken down rapidly in the body.
Clinical trials have established the efficacy of tositumomab in patients with relapsed follicular lymphoma.
It is manufactured by Corixa. It sells in the U.S. under the trade name Bexxar.
 | This medical treatment–related article is a stub. You can help Wikipedia by expanding it. |